↓ Skip to main content

Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study

Overview of attention for article published in Nagoya journal of medical science, August 2019
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter
1 X user

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
23 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study
Published in
Nagoya journal of medical science, August 2019
DOI 10.18999/nagjms.81.3.359
Pubmed ID
Authors

Joe Senda, Keiichi Ito, Tomomitsu Kotake, Masahiko Kanamori, Hideo Kishimoto, Izumi Kadono, Hiroko Nakagawa-Senda, Kenji Wakai, Masahisa Katsuno, Yoshihiro Nishida, Naoki Ishiguro, Gen Sobue

Abstract

Cilostazol is a phosphodiesterase III-inhibiting antiplatelet agent that is often used to prevent stroke and peripheral artery disease, and its administration has shown significant improvements for cognitive impairment. We investigate the potential of cilostazol for reducing or restoring cognitive decline during convalescent rehabilitation in patients with non-cardioembolic ischemic stroke. The study sample included 371 consecutive patients with lacunar (n = 44) and atherothrombosis (n = 327) subtypes of non-cardioembolic ischemic stroke (224 men and 147 women; mean age, 72.9 ± 8.1 years) who were required for inpatient convalescent rehabilitation. Their medical records were retrospectively surveyed to identify those who had received cilostazol (n = 101). Patients were grouped based on cilostazol condition, and Functional Independence Measure (FIM) scores (total and motor or cognitive subtest scores) were assessed both at admission and discharge. The gain and efficiency in FIM cognitive scores from admission to discharge were significantly higher in patients who received cilostazol than those who did not (p = 0.047 and p = 0.035, respectively); we found no significant differences in other clinical factors or scores. Multiple linear regression analysis confirmed that cilostazol was a significant factor in FIM cognitive scores at discharge (β = 0.041, B = 0.682, p = 0.045); the two tested dosages were not significantly different (100 mg/day, n = 43; 200 mg/day, n = 58). Cilostazol can potentially improve cognitive function during convalescent rehabilitation of patients with non-cardioembolic ischemic stroke, although another research must be needed to confirm this potential.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 13%
Researcher 3 13%
Other 2 9%
Unspecified 2 9%
Lecturer 1 4%
Other 5 22%
Unknown 7 30%
Readers by discipline Count As %
Nursing and Health Professions 4 17%
Unspecified 2 9%
Medicine and Dentistry 2 9%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Psychology 1 4%
Other 3 13%
Unknown 10 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 October 2019.
All research outputs
#20,667,544
of 25,385,509 outputs
Outputs from Nagoya journal of medical science
#110
of 190 outputs
Outputs of similar age
#273,422
of 359,381 outputs
Outputs of similar age from Nagoya journal of medical science
#2
of 7 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 190 research outputs from this source. They receive a mean Attention Score of 3.8. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,381 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.